Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) participated in a Virtual Investor “What This Means” segment on Nov. 6, 2025 to discuss a recently announced partnership with Cellipont Bioservices.

The agreement covers Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for ovarian cancer, into clinical manufacturing and clinical trials. President and CEO Sanjeev Luther represented the company in the segment. The presentation recording is available via the Virtual Investor platform.

News Market Reaction

+2.42%

3 alerts

+2.42% News Effect

+3.7% Peak Tracked

+$334K Valuation Impact

$14M Market Cap

0.0x Rel. Volume

On the day this news was published, ERNA gained 2.42%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.7% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $334K to the company's valuation, bringing the market cap to $14M at that time.

Data tracked by StockTitan Argus on the day of publication.

Access the “What This Means” segment here

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor "What This Means" segment.

As part of the segment, Sanjeev Luther, President and CEO of Ernexa, discussed the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.

The Virtual Investor “What This Means” segment featuring Ernexa can be accessed here.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

What did Ernexa (ERNA) announce on Nov. 6, 2025 regarding Cellipont Bioservices?

Ernexa announced a partnership with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) to advance ERNA-101 toward clinical manufacturing and trials.

What is ERNA-101 and what stage will the Cellipont partnership support for ERNA-101?

ERNA-101 is Ernexa’s lead cell therapy for ovarian cancer; the partnership will support EDP activities to move it into clinical manufacturing and clinical trials.

Who spoke for Ernexa during the Virtual Investor “What This Means” segment on Nov. 6, 2025?

Sanjeev Luther, President and CEO of Ernexa, represented the company in the Virtual Investor segment.

Where can investors watch Ernexa’s Virtual Investor presentation about the Cellipont partnership?

The Virtual Investor “What This Means” segment featuring Ernexa is available to access on the Virtual Investor platform.

Does the announcement include financial terms or a clinical timeline for ERNA-101?

No financial terms or specific clinical timelines were disclosed in the announcement; it describes EDP activities to advance ERNA-101 toward clinical manufacturing and trials.